{"address1": "675 West Kendall Street", "address2": "Henri A. Termeer Square", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 551 8200", "fax": "617 551 8101", "website": "https://www.alnylam.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 2230, "companyOfficers": [{"maxAge": 1, "name": "Dr. Yvonne L. Greenstreet M.B.A., M.D.", "age": 61, "title": "CEO & Director", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 4253570, "exercisedValue": 5727380, "unexercisedValue": 17191740}, {"maxAge": 1, "name": "Dr. Phillip A. Sharp Ph.D.", "age": 79, "title": "Co-Founder, Member of the Scientific Advisory Board & Independent Director", "yearBorn": 1945, "fiscalYear": 2024, "totalPay": 105000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeffrey V. Poulton M.B.A.", "age": 56, "title": "CFO & Executive VP", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 1433740, "exercisedValue": 0, "unexercisedValue": 26040664}, {"maxAge": 1, "name": "Dr. Kevin Joseph Fitzgerald Ph.D.", "age": 55, "title": "Executive VP, Chief Scientific Officer and Head of Early Research & Early Development", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 1225300, "exercisedValue": 3769372, "unexercisedValue": 6797953}, {"maxAge": 1, "name": "Dr. Pushkal P. Garg M.D.", "age": 56, "title": "Chief Medical Officer and Executive VP of Development & Medical Affairs", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 1421120, "exercisedValue": 0, "unexercisedValue": 22391564}, {"maxAge": 1, "name": "Mr. Tolga  Tanguler M.B.A.", "age": 51, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 1306670, "exercisedValue": 0, "unexercisedValue": 5872630}, {"maxAge": 1, "name": "Mr. Timothy J. Maines", "title": "Chief Technical Operations & Quality Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Piyush  Sharma J.D.", "title": "Chief Ethics & Compliance Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert W. Hesslein Esq., J.D.", "age": 71, "title": "Executive VP, Chief Legal Officer & Corporate Secretary", "yearBorn": 1953, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine Regan Lindenboom", "age": 42, "title": "Chief Corporate Communications Officer", "yearBorn": 1982, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 2, "compensationRisk": 5, "shareHolderRightsRisk": 6, "overallRisk": 4, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 270.02, "open": 272.52, "dayLow": 255.13, "dayHigh": 273.605, "regularMarketPreviousClose": 270.02, "regularMarketOpen": 272.52, "regularMarketDayLow": 255.13, "regularMarketDayHigh": 273.605, "payoutRatio": 0.0, "beta": 0.391, "forwardPE": -209.63933, "volume": 867682, "regularMarketVolume": 867682, "averageVolume": 797698, "averageVolume10days": 1244920, "averageDailyVolume10Day": 1244920, "bid": 255.14, "ask": 256.79, "bidSize": 1, "askSize": 1, "marketCap": 33102247936, "fiftyTwoWeekLow": 141.98, "fiftyTwoWeekHigh": 304.39, "priceToSalesTrailing12Months": 14.723608, "fiftyDayAverage": 260.2954, "twoHundredDayAverage": 256.61475, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 33158877184, "profitMargins": -0.12372, "floatShares": 124460110, "sharesOutstanding": 129427000, "sharesShort": 2538284, "sharesShortPriorMonth": 3218951, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0196, "heldPercentInsiders": 0.03874, "heldPercentInstitutions": 0.96391, "shortRatio": 3.48, "shortPercentOfFloat": 0.025999999, "impliedSharesOutstanding": 135076000, "bookValue": 0.519, "priceToBook": 492.79382, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -278156992, "trailingEps": -2.17, "forwardEps": -1.22, "enterpriseToRevenue": 14.749, "enterpriseToEbitda": -275.83, "52WeekChange": 0.69568384, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 255.76, "targetHighPrice": 500.0, "targetLowPrice": 206.0, "targetMeanPrice": 314.16776, "targetMedianPrice": 320.0, "recommendationMean": 1.9697, "recommendationKey": "buy", "numberOfAnalystOpinions": 31, "totalCash": 2694503936, "totalCashPerShare": 20.814, "ebitda": -120215000, "totalDebt": 2743418880, "quickRatio": 2.613, "currentRatio": 2.778, "totalRevenue": 2248242944, "debtToEquity": 4089.284, "revenuePerShare": 17.612, "returnOnAssets": -0.0274, "grossProfits": 1924872960, "freeCashflow": 197879632, "operatingCashflow": -8312000, "revenueGrowth": 0.349, "grossMargins": 0.85616994, "ebitdaMargins": -0.05347, "operatingMargins": -0.17728001, "financialCurrency": "USD", "symbol": "ALNY", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1086096600000, "preMarketChange": -0.5, "preMarketChangePercent": -0.19549578, "preMarketPrice": 255.26, "marketState": "PRE", "regularMarketChangePercent": -5.2810884, "regularMarketPrice": 255.76, "shortName": "Alnylam Pharmaceuticals, Inc.", "longName": "Alnylam Pharmaceuticals, Inc.", "regularMarketChange": -14.2599945, "regularMarketDayRange": "255.13 - 273.605", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 797698, "fiftyTwoWeekLowChange": 113.78, "fiftyTwoWeekLowChangePercent": 0.8013805, "fiftyTwoWeekRange": "141.98 - 304.39", "fiftyTwoWeekHighChange": -48.63002, "fiftyTwoWeekHighChangePercent": -0.1597622, "fiftyTwoWeekChangePercent": 69.56838, "earningsTimestamp": 1736715600, "earningsTimestampStart": 1746016200, "earningsTimestampEnd": 1746448200, "earningsCallTimestampStart": 1739453400, "earningsCallTimestampEnd": 1739453400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.17, "epsForward": -1.22, "epsCurrentYear": 0.82154, "priceEpsCurrentYear": 311.31775, "fiftyDayAverageChange": -4.5354156, "fiftyDayAverageChangePercent": -0.017424108, "twoHundredDayAverageChange": -0.8547516, "twoHundredDayAverageChangePercent": -0.0033308747, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.0 - Buy", "corporateActions": [], "preMarketTime": 1743593430, "regularMarketTime": 1743537602, "exchange": "NMS", "messageBoardId": "finmb_2796659", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Alnylam Pharmaceuticals", "trailingPegRatio": null}